<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03027635</url>
  </required_header>
  <id_info>
    <org_study_id>PETRA21042016</org_study_id>
    <nct_id>NCT03027635</nct_id>
  </id_info>
  <brief_title>PEriToneal Catheter Versus Repeated Paracentesis for Ascites in Cirrhosis</brief_title>
  <acronym>PETRA</acronym>
  <official_title>Tunnelated Peritoneal Catheter Versus Repeated Large Volume Paracentesis for Diuretic Resistant Ascites in Patients With Cirrhosis: An Investigator Initiated, Open, Parallel Arm Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nina Kimer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Copenhagen University Hospital, Hvidovre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insertion of a tunnelated peritoneal catheter (PleurX) allows repeated intermittent small&#xD;
      volume fluid drainage at home. The treatment may improve the management of ascites and have a&#xD;
      beneficial effect on the quality of life.&#xD;
&#xD;
      This study aims to evaluate the beneficial and harmful effects of the peritoneal catheter&#xD;
      (PleurX) versus repeated large volume paracentesis for patients with cirrhosis and diuretic&#xD;
      resistant ascites.&#xD;
&#xD;
      The trial is an investigator initiated, randomised, single blind, parallel arm, controlled&#xD;
      trial.&#xD;
&#xD;
      Tunnelated peritoneal (PleurX) catheter versus large volume paracentesis. All patients will&#xD;
      receive ciprofloxacin to prevent spontaneous bacterial peritonitis.&#xD;
&#xD;
      We will include 32 adult patients with cirrhosis Duration of trial 18 months. The total&#xD;
      duration of follow up is six months. The primary outcome is paracentesis free survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ten percent of patients with cirrhosis develop ascites. In 90% of patients, ascites can be&#xD;
      treated with diuretics. The management of the remaining 10% with diuretic resistant ascites&#xD;
      is challenging. Symptoms including abdominal pain, dyspnoea, nausea, vomiting, and anorexia&#xD;
      have a detrimental impact on the quality of life. Repeated large volume paracentesis provides&#xD;
      only temporary improvement of symptoms.&#xD;
&#xD;
      Insertion of a tunnelated peritoneal catheter (PleurX) allows repeated intermittent small&#xD;
      volume fluid drainage at home. The treatment may improve the management of ascites and have a&#xD;
      beneficial effect on the quality of life.&#xD;
&#xD;
      To evaluate the beneficial and harmful effects of the peritoneal catheter (PleurX) versus&#xD;
      repeated large volume paracentesis for patients with cirrhosis and diuretic resistant&#xD;
      ascites.&#xD;
&#xD;
      Investigator initiated, randomised, single blind, parallel arm, controlled trial.&#xD;
&#xD;
      Due to the nature of the intervention and the primary outcome measure, Investigators are&#xD;
      unable to conduct the trial with blinding of the patients, the investigators or use blinded&#xD;
      outcome assessment.&#xD;
&#xD;
      Tunnelated peritoneal (PleurX) catheter versus large volume paracentesis. All patients will&#xD;
      receive ciprofloxacin to prevent spontaneous bacterial peritonitis.&#xD;
&#xD;
      The study investigators will include 32 adult patients with cirrhosis of any aetiology and&#xD;
      diuretic resistant ascites.&#xD;
&#xD;
      Gastrounit, Hvidovre University Hospital, Department of Gastroenterology and Hepatology,&#xD;
      Odense University Hospital, Department of Gastroenterology and Hepatology, Aarhus University&#xD;
      Hospital, and Centre for Hepatology, UCL Institute for Liver and Digestive Health, Royal Free&#xD;
      Campus, University College London, UK 18 months. The total duration of follow up is six&#xD;
      months. The primary outcome is paracentesis free survival. Secondary outcomes include&#xD;
      cumulative number of paracentesis, cirrhosis-related complications, safety, quality of life,&#xD;
      changes in metabolic and nutritional parameters, circulatory dysfunction, renal function,&#xD;
      cardiac output, neuro-humoral changes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment and limited funding. The treatment intervention is instituted in clinical&#xD;
    practice as and end-stage treatment option at hospitals in Denmark&#xD;
  </why_stopped>
  <start_date type="Actual">January 20, 2017</start_date>
  <completion_date type="Actual">May 15, 2019</completion_date>
  <primary_completion_date type="Actual">May 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first paracentesis</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>18 months</time_frame>
    <description>Number of AEs in groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional Status</measure>
    <time_frame>18 months</time_frame>
    <description>Indirect calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>18 months</time_frame>
    <description>glomerular filtration rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Output</measure>
    <time_frame>18 months</time_frame>
    <description>cardiac output</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Ascites Hepatic</condition>
  <condition>Ascites (Non-Malignant)</condition>
  <arm_group>
    <arm_group_label>PleurX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The PleurX catheter is a tunnelated peritoneal catheter, designed for permanent placement in the peritoneal cavity. The catheter is placed by a physician under sterile conditions. Drainage of ascites is done using vacuum bottles connected to the catheter. This can be managed by a home nurse or the patient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Large Volume Paracentesis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Large volume paracentesis is performed in sterile technique, a small incision is made through the skin, and a catheter is inserted through muscle and peritoneum. After the procedure, the patient remains in hospital for observation until the fluid is drained.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PleurX, peritoneal tunnelated catheter</intervention_name>
    <description>A permanent catheter</description>
    <arm_group_label>PleurX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Large Volume Paracentesis</intervention_name>
    <description>Short time drainage</description>
    <arm_group_label>Large Volume Paracentesis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin 500Mg Tablet</intervention_name>
    <description>SBP prophylaxis</description>
    <arm_group_label>Large Volume Paracentesis</arm_group_label>
    <arm_group_label>PleurX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cirrhosis of any aetiology&#xD;
&#xD;
          -  Diuretic resistant ascites defined as i) an inability to mobilise ascites (minimal or&#xD;
             no weight loss) despite administration with the maximum tolerable doses of oral&#xD;
             diuretics or a daily dose of spironolactone 400 mg and re-accumulation of fluid after&#xD;
             therapeutic paracentesis within two weeks or ii) diuretic-related complications&#xD;
             including (but not limited to) azotemia, hepatic encephalopathy, or progressive&#xD;
             electrolyte imbalances&#xD;
&#xD;
          -  Able to read and understand Danish&#xD;
&#xD;
          -  Signed and dated informed consent form&#xD;
&#xD;
          -  Willing to comply with all study procedures and be available for the duration of the&#xD;
             study&#xD;
&#xD;
          -  Male or female of any age&#xD;
&#xD;
          -  Age at least 18 years&#xD;
&#xD;
          -  Expected survival at least three months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants eligible and listed for TIPS&#xD;
&#xD;
          -  Serum creatinine levels above 135 umol/L&#xD;
&#xD;
          -  Overt hepatic encephalopathy in the two weeks before randomization&#xD;
&#xD;
          -  Ascites due to other causes than cirrhosis such as: malignant disease, congestive&#xD;
             heart failure, end-stage renal disease, pancreatitis, or Budd-Chiari (hepatic vein&#xD;
             thrombosis), or chylous ascites&#xD;
&#xD;
          -  Ongoing intra-abdominal infection (peritonitis) or active systemic or local&#xD;
             infections, such as urinary tract infection or pneumonia&#xD;
&#xD;
          -  Participation in a clinical study that may interfere with participation in this study;&#xD;
&#xD;
          -  Evidence of extensive ascites loculation&#xD;
&#xD;
          -  Coagulopathy&#xD;
&#xD;
          -  Variceal bleeding within two weeks before randomisation&#xD;
&#xD;
          -  Intraabdominal surgery within four months before randomisation&#xD;
&#xD;
          -  Spontaneous bacterial peritonitis (neutrophil count&gt;250/µl within 24 hours of&#xD;
             randomization)&#xD;
&#xD;
          -  Patients with an increased risk of procedure related complications as judged by the&#xD;
             primary healthcare provider&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gastro Unit, medical Division, University Hospital Hvidovre</name>
      <address>
        <city>Hvidovre</city>
        <state>Danmark</state>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>December 13, 2016</study_first_submitted>
  <study_first_submitted_qc>January 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2017</study_first_posted>
  <last_update_submitted>May 16, 2019</last_update_submitted>
  <last_update_submitted_qc>May 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Copenhagen University Hospital, Hvidovre</investigator_affiliation>
    <investigator_full_name>Nina Kimer</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>diuretic resistant ascites</keyword>
  <keyword>Paracentesis</keyword>
  <keyword>PleurX</keyword>
  <keyword>Peritoneal tunnelated catheter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Due to Danish Legislation only anonymized data may be available upon request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

